Harvard spinout Emulate will use the cash to further develop its organ-on-a-chip technology, having now raised nearly $225m in total.

Emulate, a US-based biotechnology developer spun out of Harvard University, raised $82m in a series E round led Northpond Ventures on Tuesday. Perceptive Advisors also contributed funding, bringing the company’s total capital to almost $225m. Emulate is developing in vitro on-a-chip models of human organs that replicate their function, in order to aid research in…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.